Ann Arbor, Mich. Lehigh Valley, Pa.,
15:06 PM

Strata Oncology and Lehigh Valley Health Network Announce Partnership to Increase Access to Cutting-Edge Precision Medicine for Patients with Advanced Cancer

Relationship will provide every advanced solid tumor patient at LVHN the opportunity to benefit from precision medicine

Strata Oncology, a precision oncology company, announced that Lehigh Valley Health Network (LVHN) is among five health systems and the only one in the Lehigh Valley region joining the Strata Precision Oncology Network™ (the “Network”). The others are Baptist Health (Kentucky), MultiCare Health System (Washington), Prisma Health (South Carolina) and Marshfield Clinic (Wisconsin).

Routine tumor molecular profiling through the Strata Trial, which began July 12 at Lehigh Valley Hospital-Cedar Crest and Lehigh Valley Hospital-Muhlenberg, will now be available at more than 100 hospitals across the Strata Precision Oncology Network, covering 140,000 newly diagnosed cancer patients annually. Strata Oncology’s growing portfolio of pharma-sponsored clinical trials will be available to eligible patients at the Lehigh Valley Cancer Institute.

“The addition of these health systems to the Network expands our reach to 40,000 patients each year with newly diagnosed advanced disease,” said Dan Rhodes, Ph.D., CEO of Strata Oncology. “Together we are working to solve the unique hurdles integrated health systems face in implementing a large-scale precision oncology program, including routine tumor profiling, rapid interpretation of test results, and local access to precision therapy trials.”

Despite recent advances in cancer care and treatment, most advanced cancer patients do not have access to comprehensive tumor molecular profiling and precision medicine clinical trials. At the same time, precision therapy trial enrollment is slow and inefficient, resulting in delays bringing new medicines to market.

Strata Oncology launched the Network in 2017, committed to creating a new standard of care for cancer patients, one where molecular profiling, clinical trial participation and continuous learning to inform care and research is the norm.

“Lehigh Valley Health Network has a longstanding commitment to deliver high-level care to cancer patients across eastern Pennsylvania,” said Suresh Nair, M.D., physician-in-chief of the Lehigh Valley Cancer Institute. “This partnership positions Lehigh Valley Cancer Institute on the cutting-edge of providing patients access to the latest technology and clinical research in precision oncology.”

Nair said LVHN will be able to offer Strata testing at no cost, and that the test features an expanded gene panel, from 90 to 500 cancer genes, and includes analytical validation of 36 emerging gene expression biomarkers, compared to commercial gene sequencing tests that can cost patients as much as $5,000 in copays. Nair said that as many as 1,000 LVHN patients may benefit from as much as $5 million of free testing yearly for three years of current funding.

About Strata Oncology

Strata Oncology, Inc. is a precision medicine company dedicated to transforming cancer care by building a platform to systematize precision oncology across a network of health systems and pharma companies. Strata empowers health systems to deliver a cost-effective, system-wide, precision oncology program, one that integrates cutting-edge molecular profiling and precision therapy trials with routine care, so that all advanced cancer patients have the opportunity to benefit. This large network of trial-ready health systems provides a mechanism to rapidly and predictably enroll precision therapy trials. For more information visit

About the Strata Precision Oncology Network

The Strata Precision Oncology Network (“Network”), led by Strata Oncology, is a collaborative network of leading health systems that believe in deploying a clinical-research driven model for precision medicine that enables continuous learning to drive research and clinical care. The Network consists of 18 leading health systems that have demonstrated a commitment to standardizing tumor molecular profiling and precision therapy trials, providing a platform to accelerate drug approvals and catalyze new clinical research opportunities. The Strata Trial serves as the foundation of this approach by providing a standardized genomic testing protocol to deliver precision oncology system-wide.